Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success

Analysts have lifted the average price target for Vir Biotechnology to about $21.56 from $20.67, citing a slightly higher revenue growth outlook and a richer future P/E assumption as they factor in potential benefits from emerging hepatitis delta virus therapies following recent U.S. approval of bulevirtide.

Analyst Commentary

Recent research on Vir Biotechnology points to a more constructive stance on the stock, with the updated price target anchored in expectations around the hepatitis delta virus opportunity and how effectively the company can turn that pipeline into commercial revenue.

Bullish Takeaways

• Bullish analysts see the higher price target as reflecting stronger conviction that Vir Biotechnology can capture value from hepatitis delta virus therapies, supported by what they view as a richer but still reasonable future P/E assumption.
• The recent U.S. approval of bulevirtide is viewed as an important proof point that this underdiagnosed condition can support a commercial market. In their view, this improves the long term growth profile underpinning Vir Biotechnology's valuation.
• On execution, bullish analysts argue that Vir Biotechnology and Mirum are positioned as the next wave of therapies in hepatitis delta virus. They see this as a relative advantage when assessing potential market share and future earnings power.
• The reset to a higher target range is framed as aligning the stock more closely with peers pursuing similar rare disease and hepatology indications, based on anticipated revenue contribution from these programs over time.

Bearish Takeaways

• Some cautious analysts have previously trimmed price targets, signaling concern that execution risk around development timelines, diagnostics uptake and commercial rollout for hepatitis delta virus therapies could limit how quickly Vir Biotechnology translates its pipeline into earnings.
• The emphasis on a richer future P/E assumption highlights that a portion of the valuation is based on expectations rather than current cash flows, which leaves less room for missteps if clinical or regulatory outcomes differ from current views.
• The focus on an underdiagnosed condition implies dependence on better disease awareness and testing infrastructure, which more cautious analysts see as a potential drag on the pace of adoption and revenue realization.
• There is an implicit risk that if competing therapies, including those from Mirum, perform differently than expected on efficacy, safety or pricing, the share of the hepatitis delta virus market available to Vir Biotechnology could come in below current bullish projections.

What’s in the News for Vir Biotechnology

• Vir Biotechnology and Astellas closed their global collaboration and licensing agreement for VIR-5500, with Vir receiving a US$240 million upfront payment, a US$75 million equity investment at US$10.36 per share, a near-term US$20 million milestone payment, eligibility for up to an additional US$1.37b in milestones, and tiered double-digit royalties on ex US sales, with a portion of certain proceeds shared with Sanofi. (Source: Company announcement)
• Recent coverage of Vir Biotechnology highlights VIR-5500, a PSMA targeted T cell engager for metastatic castration resistant prostate cancer. The therapy uses PRO XTEN masking technology intended to reduce systemic toxicity and cytokine release syndrome and enable higher dosing, supported by early Phase 1 clinical results and the Astellas collaboration valued at up to US$1.7b including a premium equity investment. (Source: “Is Vir Biotechnology, Inc. (VIR) A Good Stock To Buy Now?”)
• Vir Biotechnology plans to present data from the Phase 2 SOLSTICE trial of the tobevibart and elebsiran combination for chronic hepatitis delta at the EASL Congress 2026 in Barcelona. The data will cover an investigational regimen designed to interfere with the hepatitis delta virus life cycle by targeting both viral entry and hepatitis B surface antigen. (Source: Company announcement)
• The company reports progress in its oncology pipeline with the first patient dosed in one of three expansion cohorts in the Phase 1 trial of VIR-5500 in metastatic castration resistant prostate cancer. This follows monotherapy dose escalation data that showed a favorable safety profile and anti tumor activity, with further combination cohorts and later phase trials planned. (Source: Company announcement)
• Brii Biosciences has filed a demand for arbitration against Vir Biotechnology related to their collaboration and license agreements around the elebsiran program, alleging breach of contract and seeking performance of manufacturing transfer obligations along with damages and lost profits. The company states it will continue to pursue legal remedies. (Source: Company announcement)

Valuation Changes for Vir Biotechnology

• Fair Value: Updated consensus fair value has risen slightly from $20.67 to $21.56 per share.
• Discount Rate: The discount rate assumption has edged higher from 7.22% to 7.27%, indicating a modestly higher required return in the model.
• Revenue Growth: Forecast revenue growth has been adjusted slightly upward from 37.11% to 37.76%.
• Net Profit Margin: Assumed net profit margin has been trimmed marginally from 19.04% to 18.98%.
• Future P/E: The future P/E multiple used in the valuation has increased from 163.3x to 168.6x, reflecting a somewhat richer earnings multiple assumption for Vir Biotechnology.